The estimated Net Worth of Corazon (Corsee) D. Sanders is at least $584 mil dollars as of 2 July 2024. Corazon Sanders owns over 584 units of Molecular Templates Inc stock worth over $16,452 and over the last 5 years he sold MTEM stock worth over $304,759. In addition, he makes $263,073 as Independent Director at Molecular Templates Inc.
Sign up
Corazon Sanders MTEM stock SEC Form 4 insiders trading
Corazon has made over 5 trades of the Molecular Templates Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 584 units of MTEM stock worth $23,932 on 2 July 2024.
The largest trade he's ever made was selling 1,737 units of Molecular Templates Inc stock on 10 June 2024 worth over $71,391. On average, Corazon trades about 276 units every 22 days since 2019. As of 2 July 2024 he still owns at least 12,009 units of Molecular Templates Inc stock.
You can see the complete history of Corazon Sanders stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Corazon Sanders biography
Dr. Corazon Dating Sanders Ph.D. serves as Independent Director of the Company. Dr. Sanders serves as a Strategic Advisor to the Global Development Group of Bristol Myers Squibb, a position she has held since November 2019. Previously, Dr. Sanders served as Strategic Advisor to the Office of the Celgene Chief Medical Officer, since March 2018, ensuring effective integration of Juno Therapeutics’ Development Organization into the Celgene Organization, specifically the unique CAR T aspects, advising the label-enabling CAR T legacy Juno program (JCAR017), and advising the Chief Medical Officer and the Chief Medical Officer’s leadership team in evolving the clinical development organization. From January 2017 to March 2018, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations. Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2011 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017, with responsibility for leading nearly 2,500 employees, across 5 strategic and 20 local country sites, in planning and conducting global development and local clinical trials in over 70 countries. She was Global Head of the Genentech/Roche Biometrics group from 2009 to 2012, and Genentech Head of DATA (Design, Analysis, Technology & Administration) prior to the Roche acquisition. Earlier in her career, she was employed at Schering-Plough Research Institute and at Centocor Inc., primarily in statistician and biomedical operations roles
What is the salary of Corazon Sanders?
As the Independent Director of Molecular Templates Inc, the total compensation of Corazon Sanders at Molecular Templates Inc is $263,073. There are 8 executives at Molecular Templates Inc getting paid more, with Eric Poma having the highest compensation of $1,733,740.
How old is Corazon Sanders?
Corazon Sanders is 63, he's been the Independent Director of Molecular Templates Inc since 2019. There are 2 older and 17 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.
What's Corazon Sanders's mailing address?
Corazon's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Insiders trading at Molecular Templates Inc
Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch y Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.
What does Molecular Templates Inc do?
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
What does Molecular Templates Inc's logo look like?
Complete history of Corazon Sanders stock trades at BeiGene Ltd, Ultragenyx Pharmaceutical y Molecular Templates Inc
Molecular Templates Inc executives and stock owners
Molecular Templates Inc executives and other stock owners filed with the SEC include:
-
Eric Poma,
Chief Executive Officer, Chief Scientific Officer, Director -
Roger Waltzman,
Chief Medical Officer -
Jason Kim,
President, Chief Operating Officer -
Adam Cutler,
Chief Financial Officer, Treasurer, Secretary -
Dr. Eric E. Poma,
CEO, Chief Scientific Officer & Director -
Dr. Roger J. Waltzman M.B.A., M.D.,
Chief Medical Officer -
Jason S Kim,
Pres & COO -
Dr. Roger J. Waltzman,
Chief Medical Officer -
Corazon Sanders,
Independent Director -
Harold Selick,
Chairman of the Board -
Kevin Lalande,
Independent Director -
David Hirsch,
Independent Director -
David Hoffmann,
Independent Director -
Scott Morenstein,
Independent Director -
Jonathan Lanfear,
Independent Director -
Michael Dowd,
Sr. VP of Project & Alliance Management -
Megan C. Filoon,
Gen. Counsel & Sec. -
Dr. Nenad Sarapa M.D., M.S.,
Sr. VP of Clinical Devel. -
Dr. Jen-Sing Liu Ph.D.,
Exec. VP of Manufacturing -
Dr. Erin Willert Ph.D.,
Exec. VP of R&D -
Dr. Jack Higgins Ph.D.,
Exec. VP of Operations & Head of Manufacturing -
Kurt Elster,
Exec. VP of Corp. Devel. -
Sean McLennan,
Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer -
Associates, L.L.C.Morenstei...,
-
Target N Vbb Biotech Ag Bio...,
-
Dave Hoffmann,
Director -
Capital Partners Iii, Llc L...,
-
Scott Dcdk Associates, L.L....,
-
Management Services, Llc Cu...,
-
Sean Mc Lennan,
See remarks -
Management Services, Llc Cu...,
-
Gabriela Gruia,
Director -
Maurizio Voi,
Chief Medical Officer